Holen Sie sich die Stockscreener-App
45.25
3.22%
1.41
Vorhandelsmarkt:
44.71
-0.54
-1.19%
Schlusskurs vom Vortag:
$43.84
Offen:
$44.27
24-Stunden-Volumen:
774.48K
Relative Volume:
1.08
Marktkapitalisierung:
$3.33B
Einnahmen:
$900.66M
Nettoeinkommen (Verlust:
$-453.20M
KGV:
-7.6178
EPS:
-5.94
Netto-Cashflow:
$-274.19M
1W Leistung:
+8.23%
1M Leistung:
-2.14%
6M Leistung:
+38.68%
1J Leistung:
+67.22%
1-Tages-Spanne:
$42.97
$45.28
1-Wochen-Bereich:
$41.75
$45.28
52-Wochen-Spanne:
$23.58
$54.16
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Firmenname
Ptc Therapeutics Inc
Sektor
Branche
Telefon
(908) 222-7000
Adresse
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Vergleichen Sie PTCT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
45.25 | 3.33B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-13 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-09-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-08-26 | Fortgesetzt | UBS | Buy |
| 2024-05-20 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-30 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Herabstufung | Citigroup | Neutral → Sell |
| 2023-10-06 | Herabstufung | Truist | Buy → Hold |
| 2023-09-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-09-15 | Herabstufung | Raymond James | Outperform → Underperform |
| 2023-03-17 | Eingeleitet | SVB Securities | Market Perform |
| 2022-12-14 | Eingeleitet | Goldman | Sell |
| 2022-09-12 | Eingeleitet | Jefferies | Buy |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-03-29 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-01-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-11-30 | Herabstufung | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-10-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-04-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-02-20 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-05-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Eingeleitet | Bernstein | Outperform |
| 2018-10-03 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Eingeleitet | Credit Suisse | Outperform |
| 2018-06-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Herabstufung | JP Morgan | Neutral → Underweight |
Alle ansehen
Ptc Therapeutics Inc Aktie (PTCT) Neueste Nachrichten
PTC Therapeutics Stock Soars on Novartis Licensing Agreement - MSN
Assenagon Asset Management S.A. Sells 52,794 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Gastroparesis Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and FDA Approvals | CinDome Pharma, Inc., Evoke Pharma, Vanda Pharma, Ironwood Pharma, Takeda, Neurogastrx, Inc, PTC Thera - The Globe and Mail
William Blair Boosts Earnings Estimates for PTC Therapeutics - MarketBeat
PTC Therapeutics' SWOT analysis: rare disease biotech stock faces pivotal year - Investing.com Australia
Cantor Fitzgerald Issues Pessimistic Forecast for PTC Therapeutics (NASDAQ:PTCT) Stock Price - MarketBeat
PTC Therapeutics sees several potential catalysts in 2025 - MSN
Orsini the Exclusive Specialty Pharmacy Provider for Gene Therapy KEBILIDI™ (eladocagene exuparvovec-tneq) - Yahoo Finance
Muscular Dystrophy Treatment Market Next Big Thing Forecast By 2031 | Santhera Pharmaceuticals, PTC Therapeutics - openPR
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
PTC Therapeutics Surpasses Revenue Guidance for 2024 - TipRanks
PTC Therapeutics reports $814 million in 2024 revenue, surpassing goals - Investing.com
PTC Therapeutics reports $814 million in 2024 revenue, surpassing goals By Investing.com - Investing.com South Africa
PTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare Conference - Longview News-Journal
Ptc Therapeutics' chief accounting officer sells $132,492 in stock - Investing.com India
Ptc Therapeutics' chief accounting officer sells $132,492 in stock By Investing.com - Investing.com South Africa
PTC Therapeutics CEO Eric Pauwels sells $167,550 in stock By Investing.com - Investing.com South Africa
Ptc Therapeutics exec VP sells shares worth $158,870 By Investing.com - Investing.com Australia
Ptc Therapeutics CEO Matthew Klein sells $204,007 in stock - Investing.com India
Ptc Therapeutics CEO Matthew Klein sells $204,007 in stock By Investing.com - Investing.com Australia
Ptc Therapeutics exec VP sells shares worth $158,870 - Investing.com India
Ptc therapeutics' EVP sells $90,036 in stock By Investing.com - Investing.com Australia
PTC Therapeutics, Inc. (NASDAQ:PTCT) EVP Lee Scott Golden Sells 810 Shares - MarketBeat
Insider Selling: PTC Therapeutics, Inc. (NASDAQ:PTCT) VP Sells 1,543 Shares of Stock - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) CAO Christine Marie Utter Sells 1,291 Shares - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Insider Neil Gregory Almstead Sells 1,265 Shares - MarketBeat
Ptc therapeutics’ EVP sells $90,036 in stock By Investing.com - Investing.com Nigeria
PTC Therapeutics CEO Eric Pauwels sells $167,550 in stock - Investing.com
Ptc Therapeutics executive Neil Almstead sells shares worth $133,674 - Investing.com
Ptc therapeutics' EVP sells $90,036 in stock - Investing.com
JPMorgan Chase & Co. Cuts Stock Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Denali Suffers Another ALS Fail With Phase II/III Flop - BioSpace
Have Insiders Sold PTC Therapeutics Shares Recently? - Simply Wall St
Where are the Opportunities in (PTCT) - Stock Traders Daily
Ptc Therapeutics CEO Matthew Klein sells $373,879 in stock By Investing.com - Investing.com Australia
Ptc Therapeutics CEO Matthew Klein sells $373,879 in stock - Investing.com India
PTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Matthew B. Klein Sells 8,279 Shares - MarketBeat
PTC Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation - Quantisnow
Brokerages Set PTC Therapeutics, Inc. (NASDAQ:PTCT) Price Target at $54.08 - MarketBeat
Long Term Trading Analysis for (PTCT) - Stock Traders Daily
PTC Therapeutics Stock Eyes Further Rally After Price-Target Hikes On Huntington’s Therapy Deal With Novartis: Retail Buzz Grows - MSN
Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion - MSN
PTC Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Geode Capital Management LLC Acquires 10,886 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC upgraded to outperform by RBC on Novartis deal - MSN
Finanzdaten der Ptc Therapeutics Inc-Aktie (PTCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):